Core Viewpoint - Sino Medical's stock price increased by 13.72% to 34.57 yuan, with a rolling PE ratio reaching a new low of 2342.49 times over the past 1230 days, while the total market value stands at 14.383 billion yuan [1][2] Company Summary - Sino Medical Technology Co., Ltd. specializes in the research, development, production, and sales of high-end interventional medical devices [1] - The company's main products include biodegradable drug-coated coronary stent systems, drug-eluting stent systems, non-compliant PTCA balloon dilatation catheters, and various other interventional devices [1] Financial Performance - For the first quarter of 2025, the company reported an operating income of 101 million yuan, representing a year-on-year increase of 10.75% [2] - The net profit for the same period was 2.9693 million yuan, showing a significant year-on-year growth of 277.50% [2] - The sales gross margin was recorded at 59.66% [2] Industry Comparison - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Sino Medical at the 123rd rank within the industry [1][2] - The company's static PE ratio is 960.26 times, and the price-to-book ratio is 16.52 [2]

8月12日，赛诺医疗今日收盘25.11元，上涨2.36%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到1701.47倍，创1174天以来新低，总市值104.47亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均57.51倍，行业中值41.25倍，赛诺医疗排 名第123位。 截至2025年一季报，共有1家机构持仓赛诺医疗，其中基金1家，合计持股数20.34万股，持股市值0.02亿 元。 赛诺医疗科学技术股份有限公司的主营业务是高端介入医疗器械研发、生产、销售。公司的主要产品是 生物降解药物涂层冠脉支架系统、药物洗脱支架系统、非顺应性PTCA球囊扩张导管、PTCA球囊扩张 导管、非顺应性球囊扩张导管、冠脉球囊扩张导管、冠状动脉棘突球囊扩张导管、延长导管、颅内药物 洗脱支架系统、颅内取栓支架、颅内球囊扩张导管、负压吸引泵、一次性使用无菌吸引延长管、远端通 路导管、颅内血栓抽吸导管、微导管、远端通路导引导管、导引导管、桡动脉通路导引系统、输送导 管、球囊导引导管。 最新一期业绩显示，2025年一季报，公司实现营业收入1.01亿元，同比10.75%；净利润296.93万元，同 比277.50 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sino Medical, noting its high PE ratio compared to industry averages [1][2] - As of May 6, Sino Medical's stock closed at 9.89 yuan, with a PE ratio of 665.98, marking a new low in 20 days, and a total market capitalization of 4.089 billion yuan [1] - The average PE ratio for the medical device industry is 48.90, with a median of 36.41, positioning Sino Medical at the 120th rank within the industry [1][2] Group 2 - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business focuses on the research, production, and sales of high-end interventional medical devices, primarily coronary stent systems and balloon dilation catheters [1] - The latest quarterly report for Q1 2025 shows Sino Medical achieved a revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a significant year-on-year growth of 277.50% with a gross margin of 59.66% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, which has a significantly high PE ratio compared to its industry peers [1][2] - As of April 21, Sainuo Medical's closing price was 9.41 yuan, with a PE ratio of 2557.77, marking a new low in 12 days, and a total market capitalization of 3.891 billion yuan [1] - The average PE ratio for the medical device industry is 47.69, with a median of 29.88, positioning Sainuo Medical at the 121st rank within the industry [1][2] Group 2 - Sainuo Medical specializes in the research, development, production, and sales of high-end interventional medical devices, with its main products including coronary stent systems and balloon dilation catheters [1] - The company's primary revenue source is the coronary drug-eluting stent system, and it has been recognized as a "Key Laboratory of Tianjin" and "Tianjin Enterprise Technology Center" [1] - For the third quarter of 2024, Sainuo Medical reported an operating income of 318 million yuan, a year-on-year increase of 30.20%, while the net profit was -6.74 million yuan, reflecting a year-on-year decline of 83.84%, with a gross profit margin of 61.29% [1]